

**EUROPEAN
CURRICULUM VITAE
FORMAT**



PERSONAL INFORMATION

Name

MARCO BREGNI, M.D.

Address

Telephone

Fax

E-mail

Nationality

Date of birth

WORK EXPERIENCE

- Dates (from – to)
- Name and address of employer
- Occupation or position held
- Main activities and responsibilities

OCT 2011-PRESENT

AO Ospedale di Circolo di Busto Arsizio, Italy

Director, Medical Oncology-Hematology Unit

Coordination of clinical activity and translational research in Medical Oncology

- Dates (from – to)
- Name and address of employer
- Occupation or position held
- Main activities and responsibilities

MARCH 2011 – SEPT 2011

San Raffaele Scientific Institute, Milan, Italy

Director, Strategic Program in Oncology

Coordination of clinical and translational research in the Department of Oncology

- Dates (from – to)
- Name and address of employer
- Occupation or position held
- Main activities and responsibilities

JUNE 2008-MARCH 2011

San Giuseppe Hospital, Milan, Italy

Director, Medical Oncology Unit

Coordination of clinical activity and translational research in Medical Oncology

- Dates (from – to)
- Name and address of employer
- Occupation or position held
- Main activities and responsibilities

OCT 2005 – JUNE 2008

San Raffaele Scientific Institute, Milan, Italy

Director, Strategic Program in Oncology

Coordination of clinical and translational research in the Department of Oncology

- Dates (from – to)
- Name and address of employer
- Occupation or position held
- Main activities and responsibilities

JAN 2001 – OCT 2005

San Raffaele Scientific Institute, Milan, Italy

Chief, Unit of Hematology and Bone Marrow Transplantation

Clinical responsibility on hematologic and BMT patients, and on clinical research

- Dates (from – to)
- Name and address of employer
- Occupation or position held
- Main activities and responsibilities

1998 – 2001

San Raffaele Scientific Institute, Milan, Italy

Deputy Chief, Unit of Hematology and Bone Marrow Transplantation

Clinical responsibility on hematologic and BMT patients, and on clinical research

- Dates (from – to)

1993 – 1998

- Name and address of employer
 - Occupation or position held
- Main activities and responsibilities
 - Dates (from – to)
- Name and address of employer
 - Occupation or position held
- Main activities and responsibilities
 - Dates (from – to)
- Name and address of employer
 - Occupation or position held
- Main activities and responsibilities

National Cancer Institute, Milan, Italy
 Deputy Director, Unit of Medical Oncology C
 Clinical responsibility on oncology patients, and on clinical research

1990 – 1993

National Cancer Institute, Milan, Italy
 Physician in staff, Unit of Medical Oncology C
 Clinical responsibility on oncology patients, and on clinical research

1984 – 1990

National Cancer Institute, Milan, Italy
 Research Associate, Unit of Medical Oncology C
 Clinical responsibility on oncology patients, and on clinical research

ACADEMIC APPOINTMENTS

- Dates (from – to)
- Name and address of employer
 - Occupation or position held
- Main activities and responsibilities
- Dates (from – to)
- Name and address of employer
 - Occupation or position held
- Main activities and responsibilities
- Dates (from – to)
- Name and address of employer
 - Occupation or position held
- Main activities and responsibilities
- Dates (from – to)
- Name and address of employer
 - Occupation or position held
- Main activities and responsibilities
- Dates (from – to)
- Name and address of employer
 - Occupation or position held
- Main activities and responsibilities

1991 – 1998

University of Milan Medical School
 Adjunct Professor in Oncology
 Teaching at post-graduate school in Medical Genetics

1999 – 2008

University Vita-Salute Medical School
 Adjunct Professor in Oncology
 Coordinator of the graduate class in Medical Oncology of the School of Medicine

2008-present

University of Milan Medical School
 Adjunct Professor in Oncology
 Teaching Medical Oncology at students of Medical School

2013

Ministry of Instruction, University and Research (MIUR)
 Achievement of National Scientific Qualification as Associate Professor in Oncology
 Sector 06/D3 – Blood Disease, Oncology and Rheumatology

INSTITUTIONAL ACTIVITIES

- Dates (from – to)
- Name and address of employer
 - Occupation or position held
- Main activities and responsibilities
- Dates (from – to)
- Name and address of employer
 - Occupation or position held
- Main activities and responsibilities

2009-PRESENT

Independent Ethics Committee, Ospedale Niguarda-Ca' Granda, Milan, Italy
 Member
 Discussion and approval of clinical studies

2005 – 2008

Independent Ethics Committee, Istituto Nazionale Tumori, Milan, Italy
 Member
 Discussion and approval of clinical studies

SCIENTIFIC SOCIETIES

- Dates (from – to)
- Name and address of employer
 - Occupation or position held
- Main activities and responsibilities

- Dates (from – to)
- Name and address of employer
 - Occupation or position held
- Main activities and responsibilities

- Dates (from – to)
- Name and address of employer
 - Occupation or position held
- Main activities and responsibilities

2007-PRESENT

ECCO-European CanCer Organisation
Member of the Advisory Council
EBMT liaison Officer

2013 - 2014

EBMT
President, EBMT Annual Meeting
Coordinating the activities of the 2014 Annual Meeting

2007- 2013

EBMT
Chairman, Solid Tumor Working Party
Coordinating the activities of stem cell transplantation in solid tumors in Europe

JOURNALS

- Dates (from – to)
- Name of the Journal
- Occupation or position held

- Dates (from – to)
- Name of the journal
- Occupation or position held

- Dates (from – to)
- Name of the journal
- Occupation or position held

2007-PRESENT

Oncology Reviews
Member of the Editorial Board

2008-PRESENT

The European Journal Of Clinical & Medical Oncology
Member of the Editorial Board

2009-PRESENT

Journal of Cancer
Member of the Editorial Board

RESEARCH FUNDS

- Dates (from – to)
- Funding Agency

2000-2003
Consiglio Nazionale Ricerche, Italy

- Dates (from – to)
- Funding Agency

2001-2003
AIRC

- Dates (from – to)
- Funding Agency

2002,2003
Italian Ministry of Health

- Dates (from – to)
- Funding Agency

2005-2007
AIRC

- Dates (from – to)
- Funding Agency

2005
Fondazione Guido Berlucci

- Dates (from – to) 2006
- Funding Agency Banca del Monte di Lombardia

- Dates (from – to) 2008-2010
- Funding Agency Alleanza contro il Cancro

- Dates (from – to) 2011-2013
- Funding Agency Fondazione Veronesi

- Dates (from – to) 2011-2014
- Funding Agency AIFA

EDUCATION AND TRAINING

- Dates (from – to) 1973-1979
- Name and type of organisation providing education and training University of Milan Medical School
- Title of qualification awarded Medical Doctor Degree (magna cum laude)

- Dates (from – to) 1979-1982
- Name and type of organisation providing education and training University of Milan Medical School
- Title of qualification awarded Board Certification in Hematology (magna cum laude)

- Dates (from – to) 1982-1986
- Name and type of organisation providing education and training University of Milan Medical School
- Title of qualification awarded Board Certification in Oncology

- Dates (from – to) 1983
- Name and type of organisation providing education and training Harvard University Medical School
- Title of qualification awarded Post-doctoral research fellow

- Dates (from – to) 2004
- Name and type of organisation providing education and training San Raffaele Scientific Institute
- Title of qualification awarded GCP training course

PERSONAL SKILLS AND COMPETENCES.

MOTHER TONGUE

ITALIAN

OTHER LANGUAGES

ENGLISH

- Reading skills
- Writing skills
- Verbal skills

excellent
excellent
excellent

SOCIAL SKILLS AND COMPETENCES

USED TO LIVE AND WORK ABROAD IN TEAM.

ORGANISATIONAL SKILLS AND COMPETENCES	USED TO COORDINATE TEAMWORK IN CLINICAL UNITS AND IN MEDICAL SCHOOL TEACHING
TECHNICAL SKILLS AND COMPETENCES	SPECIFIC COMPETENCES: ONCOLOGY, HEMATOLOGY, BONE MARROW TRANSPLANTATION, CANCER IMMUNOTHERAPY
ARTISTIC SKILLS AND COMPETENCES	ACOUSTIC GUITAR HIKING, TREKKING, SKIING
DRIVING LICENCE(S)	B
ANNEXES	Author or Coauthor of more than 150 publications in peer-reviewed journals reported in PubMed, with a global Impact Factor > 1009. Mean IF=7.36, H-index: 32

MARCO BREGNI, M.D.
SELECTED LIST OF PUBLICATIONS

Dalla Favera R, et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells.

Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824-7

Bregni M, et al. Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates.

Cancer Res. 1986 Mar;46(3):1208-13

Siena S, et al. Amantadine potentiates T lymphocyte killing by an anti-pan-T cell (CD5) ricin A-chain immunotoxin.

Blood. 1987 Jan;69(1):345-8

Bregni M, et al. Activity of a monoclonal antibody-saporin-6 conjugate against B-lymphoma cells.

J Natl Cancer Inst. 1988 Jun 1;80(7):511-7

Bregni M, et al. B-cell restricted saporin immunotoxins: activity against B-cell lines and chronic lymphocytic leukemia cells.

Blood. 1989 Feb 15;73(3):753-62

Bregni M, et al. Minimal residual disease in acute lymphoblastic leukemia detected by immune selection and gene rearrangement analysis.

J Clin Oncol. 1989 Mar;7(3):338-43

Gianni AM, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation.

Lancet. 1989 Sep 9;2(8663):580-5

Gianni AM, et al. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma.

J Clin Oncol. 1990 May;8(5):768-78

Bregni M, et al. Circulating hemopoietic progenitors mobilized by cancer chemotherapy and by rhGM-CSF in the treatment of high-grade non-Hodgkin's lymphoma.

Leukemia. 1991;5 Suppl 1:123-7

Bregni M, et al. Hematopoietic stem cell transplantation in the treatment of lymphoma.

Curr Opin Oncol. 1991 Oct;3(5):838-42

Bregni M, et al. Human peripheral blood hematopoietic progenitors are optimal targets of retroviral-mediated gene transfer.

Blood. 1992 Sep 15;80(6):1418-22

Gianni AM, et al. High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma.

J Clin Oncol. 1994 Mar;12(3):503-9

Siena S, et al. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy.

Exp Hematol. 1995 Dec;23(14):1463-71

Bregni M, et al. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.

J Clin Oncol. 1996 Feb;14(2):628-35

Di Nicola M, et al. Combined negative and positive selection of mobilized CD34 blood cells.

Br J Haematol. 1996 Sep;94(4):716-21

Gianni AM, Bregni M, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in

aggressive B-cell lymphoma.

N Engl J Med. 1997 May 1;336(18):1290-7

Gianni AM, et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results.

J Clin Oncol. 1997 Jun;15(6):2312-21

Bregni M, et al. Adenovirus vectors for gene transduction into mobilized blood CD34+ cells.

Gene Ther. 1998 Apr;5(4):465-72

Di Nicola M, Milanesi M, Magni M, et al.

Recombinant adenoviral vector-lipofectAMINE complex for gene transduction into human T lymphocytes.

Hum Gene Ther 1999 Jul 20;10(11):1875-84

Di Nicola M, Anichini A, Mortarini R, et al.

Human dendritic cells: natural adjuvants in antitumor immunotherapy.

Cytokines Cell Mol Ther 1998 Dec;4(4):265-73

Di Nicola M, Siena S, Bregni M, et al.

Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors.

Cancer Gene Ther 1998 Nov-Dec;5(6):350-6

Siena S, Bregni M, Gianni AM.

Mobilization of peripheral blood progenitor cells for autografting: chemotherapy and G-CSF or GM-CSF.

Baillieres Best Pract Res Clin Haematol. 1999 Mar;12(1):27-39.

Cavaletti G, Bogliun G, Zincone A, et al.

Neuro- and ototoxicity of high-dose carboplatin treatment in poor prognosis ovarian cancer patients.

Anticancer Res. 1998 Sep-Oct;18(5B):3797-802.

Bregni M, Di Nicola M, Siena S, et al.

Mobilized peripheral blood CD34+ cells express more amphotropic retrovirus receptor than bone marrow CD34+ cells.

Haematologica 1998 Mar;83(3):204-8

Ravagnani F, Siena S, De Reys S, et al.

Improved collection of mobilized CD34+ hematopoietic progenitor cells by a novel automated leukapheresis system.

Transfusion 1999 Jan;39(1):48-55

Corradini P, Voena C, Astolfi M, et al.

Maspain and mammaglobin are the only reliable markers for RT-PCR detection of minimal residual disease in patients with breast cancer.

Ann Oncol. 2001 Dec;12(12):1693-8

Camba L, Peccatori J, Pescarollo A, et al.

Thalidomide and thrombosis in patients with multiple myeloma.

Haematologica 2001 Oct;86(10):1108-9

Corradini P, Tarella C, Olivieri A, et al.

Reduced intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.

Blood 2002, 99:75-82

Bregni M, Dodero A, Peccatori J, et al.

Reduced-intensity hematopoietic cell allografting and escalating-dose donor lymphocyte infusions in advanced renal and breast cancer.

Blood, 2002, 99: 4234-4236

Peccatori J, Ciceri F, Bernardi M, et al.

Evidence of allogeneic graft-versus-tumor effect in prostate and ovarian cancer.

Haematologica 87 (S1) 12-14, 2002

Bonini C, Grez M, Traversari C, et al.
Safety of retroviral gene marking with a truncated NGF receptor.
Nat Med. 2003 Apr;9(4):367-9

Zambelli A, Lilleri D, Peccatori J, et al.
Reduced risk of cytomegalovirus infection following nonmyeloablative allogeneic hematopoietic cell transplantation in patients with refractory solid tumors.
Biol Blood Marrow Transplant (in press), 2005

Deola S, Scaramazza S, Sciarretta Birolo R, et al.
Mobilized Blood CD34⁺ Cells Transduced and Selected with a Clinically Applicable Protocol Reconstitute Lymphopoiesis in SCID-Hu Mice.
Hum Gene Ther. 2004 Mar;15(3):305-11

Corradini P, Doderio A, Zallio F, et al.
Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.
J Clin Oncol. 2004 Jun 1;22(11):2172-6.

Clementi R, Dagna L, Dianzani U, et al.
Inherited Perforin and Fas mutations in a patient with autoimmune lymphoproliferative syndrome and lymphoma.
New Engl J Med 2004 351(14):1419-24

Bregni M, Bernardi M, Ciceri F, et al.
Allogeneic stem cell transplantation for the treatment of advanced solid tumors.
Springer Semin Immunopathol. 2004, Sep 11

Clementi R, Locatelli F, Duprè L, et al.
A proportion of patients with lymphoma may harbor mutations of the perforin gene.
Blood. 2005 Jun 1;105(11):4424-8

Pagano L, Pulsoni A, Vignetti M, et al.
Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials.
Ann Oncol 2005 Feb;16(2):228-33

Zambelli A, Lilleri D, Pedrazzoli P, et al.
Incidence of human cytomegalovirus infection in patients with refractory solid tumors receiving nonmyeloablative allogeneic stem cell transplants versus recipients of standard SCT for hematologic malignancies.
Biol Blood Marrow Transplant. 2005 Jun;11(6):423-8

Corradini P, Zallio F, Mariotti J, et al.
Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies.
J Clin Oncol. 2005 Sep 20;23(27):6690-8

Peccatori J, Barkholt L, Demirel T, et al.
Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation.
Cancer. 2005 Oct 11; [Epub ahead of print]

Di Terlizzi S, Zino E, Mazzi B, et al.
Therapeutic and diagnostic applications of minor histocompatibility antigen HA-1 and HA-2 disparities in allogeneic hematopoietic stem cell transplantation: a survey of different populations.
Biol Blood Marrow Transplant. 2006 Jan;12(1):95-101.

Bregni M, Fleischhauer K, Bernardi M, et al.
Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer.
Bone Marrow Transplant. 2006 Feb;37(3):311-5

Briguori C, Reimers B, Sarais C, et al.

Direct intramyocardial percutaneous delivery of autologous bone marrow in patients with refractory myocardial angina.

Am Heart J. 2006 Mar;151(3):674-80.

Bengala C, Zamagni P, Pedrazzoli P, et al.

Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.

Br J Cancer. 2006 Apr 10;94(7):1016-20.

Barkholt L, Bregni M, Remberger M, et al.

Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe.

Ann Oncol. 2006 Jul;17(7):1134-40.

Clementi R, Chiocchetti A, Cappellano G, et al.

Variations of the perforin gene in patients with autoimmunity/lymphoproliferation and defective fas function.

Blood. 2006 Nov 1;108(9):3079-84

Re F, Staudacher C, Zamai L, et al.

Killer cell Ig-like receptors ligand-mismatched, alloreactive natural killer cells lyse primary solid tumors.

Cancer. 2006 Aug 1;107(3):640-8

Bregni M, Ueno NT, Childs R.

The second international meeting on allogeneic transplantation in solid tumors.

Bone Marrow Transplant. 2006 Oct;38(8):527-37.

Perfetti V, Siena S, Palladini G, et al.

Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.

Haematologica. 2006 Dec;91(12):1635-43.

Blaise D, Bregni M.

Allogeneic stem cell transplantation for solid tumors: which way forward?

Biol Blood Marrow Transplant. 2007 Jan;13 Suppl 1:73-5.

Ciceri F, Bonini C, Markt S, et al.

Anti-tumor effects of HSV-TK engineered donor lymphocytes after allogeneic stem cell transplantation.

Blood. 2007 Jun 1;109(11):4698-707

Tarella C, Zanni M, Di Nicola M, et al.

Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).

Leukemia. 2007 Aug;21(8):1802-11

Corradini P, Doderio A, Farina L, et al.

Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome.

Leukemia. 2007 Nov;21(11):2316-23

Deola S, Scaramuzza S, Birolo RS, et al.

Molecular purging of multiple myeloma cells by ex-vivo culture and retroviral transduction of mobilized-blood CD34+ cells.

J Transl Med. 2007 Jul 12;5:35

Carella AM, Bregni M.

Current role of allogeneic stem cell transplantation in breast cancer.

Ann Oncol. 2007 Oct;18(10):1591-3

Russo V, Cipponi A, Raccosta L, et al.

Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity.

J Clin Invest. 2007 Oct;117(10):3087-96

Ueno NT, Rizzo D, Demirer T, et al.

Allogeneic hematopoietic cell transplantation for metastatic breast cancer.

Bone Marrow Transplant. 2007 Dec 17

Demirer T, Barkholt L, Blaise D, Pedrazzoli P, Aglietta M, Carella AM, Bay JO, Arpacı F, Rosti G, Gurman G, Niederwieser D, and Bregni M, on behalf of the EBMT Solid Tumors Working Party.

Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors.

Nature Clinical Practice Oncology May 2008 Vol 5 No 5, 256-267

Fontana R, Bregni M, Cipponi A, et al.

Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients.

Blood 2009 Feb 19;113(8):1651-60

Bregni M, Pedrazzoli P.

Re: 'A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small-cell lung cancer: a randomized trial'.

J Natl Cancer Inst. 2009 Feb 19;113(8):1651-60

Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, Scaramuzza S, Andolfi G, Mirolo M, Brigida I, Tabucchi A, Carlucci F, Eibl M, Aker M, Slavin S, Al-Mousa H, Al Ghonaium A, Ferster A, Duppenhaler A, Notarangelo L, Wintergerst U, Buckley RH, Bregni M, Markt S, Valsecchi MG, Rossi P, Ciceri F, Miniero R, Bordignon C, Roncarolo MG. Gene therapy for immunodeficiency due to adenosine deaminase deficiency.

N Engl J Med. 2009 Jan 29;360(5):447-58.

Aglietta M, Barkholt L, Schianca FC, Caravelli D, Omazic B, Minotto C, Leone F, Hentschke P, Bertoldero G, Capaldi A, Ciccone G, Niederwieser D, Ringdén O, Demirer T; EBMT Solid Tumor Working Party.

Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European Group for Blood and Marrow Transplantation experience.

Biol Blood Marrow Transplant. 2009 Mar;15(3):326-35.

Bregni M, Bernardi M, Servida P, Pescarollo A, Crocchiolo R, Treppiedi E, Corradini P, Ciceri F, Peccatori J.

Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting.

Bone Marrow Transplant. 2009 Feb 23. Epub ahead of print

Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M, Turchetto L, Colombi S, Bernardi M, Peccatori J, Pescarollo A, Servida P, Magnani Z, Perna SK, Valtolina V, Crippa F, Callegaro L, Spoldi E, Crocchiolo R, Fleischhauer K, Ponzoni M, Vago L, Rossini S, Santoro A, Todisco E, Apperley J, Olavarria E, Slavin S, Weissinger EM, Ganser A, Stadler M, Yannaki E, Fassas A, Anagnostopoulos A, Bregni M, Stampino CG, Bruzzi P, Bordignon C.

Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.

Lancet Oncol. 2009 May;10(5):489-500. Epub 2009 Apr 1.

Ljungman P, Bregni M, Brune M, Cornelissen J, Witte TD, Dini G, Einsele H, Gaspar HB, Gratwohl A, Passweg J, Peters C, Rocha V, Saccardi R, Schouten H, Sureda A, Tichelli A, Velardi A, Niederwieser D

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009.

Bone Marrow Transplant. 2009 Jul 6. Epub ahead of print

Crocchiolo R, Fallanca F, Giovacchini G, Ferreri AJ, Assanelli A, Verona C, Pescarollo A, Bregni M, Ponzoni M, Gianolli L, Fazio F, Ciceri F.

Role of (18)FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma.

Ann Hematol. 2009 May 26. [Epub ahead of print]

Villablanca EJ, Raccosta L, Zhou D, Fontana R, Maggioni D, Negro A, Sanvito F, Ponzoni M, Valentinis B, Bregni M, Prinetti A, Steffensen KR, Sonnino S, Gustafsson JA, Doglioni C, Bordignon C, Traversari C, Russo V.

Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses.

Nat Med. 2009 Dec 27. [Epub ahead of print]

Bay J, Cabrespine-Faugeras A, Tabrizi R, Blaise D, Viens P, Ehninger G, Bornhauser M, Slavin S, Rosti G, Peccatori J, Demirer T, Bregni M.

Allogeneic hematopoietic stem cell transplantation in ovarian cancer the EBMT experience.

Int J Cancer. 2010 Jan 4. [Epub ahead of print]

Thiel U, Wawer A, Wolf P, Badoglio M, Santucci A, Klingebiel T, Basu O, Borkhardt A, Laws HJ, Kodera Y, Yoshimi A, Peters C, Ladenstein R, Pession A, Prete A, Urban EC, Schwinger W, Bordigoni P, Salmon A, Diaz MA, Afanasyev B, Lisukov I, Morozova E, Toren A, Bielora B, Korsakas J, Fagioli F, Caselli D, Ehninger G, Gruhn B, Dirksen U, Abdel-Rahman F, Aglietta M, Mastrodicasa E, Torrent M, Corradini P, Demeocq F, Dini G, Dreger P, Eyrich M, Gozdzik J, Guilhot F, Holler E, Koscielniak E, Messina C, Nachbaur D, Sabbatini R, Oldani E, Ottinger H, Ozsahin H, Schots R, Siena S, Stein J, Suflarska S, Unal A, Ussowicz M, Schneider P, Woessmann W, Jürgens H, Bregni M, Burdach S.

No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients.

Ann Oncol. 2011 Jul;22(7):1614-21. Epub 2011 Jan 18

Bregni M, Herr W, Blaise D; Solid Tumor Working Party of EBMT.

Allogeneic stem cell transplantation for renal cell carcinoma.

Expert Rev Anticancer Ther. 2011 Jun;11(6):901-11

Bregni M, Childs RW, Ueno NT.

Fourth Edition of the International Autologous and Allogeneic Cell Therapy for Solid Tumors.

J Cancer. 2011;2:307-8. Epub 2011 May 23

DA Berry, NT Ueno, MM Johnson, Lei X, Caputo J, Smith DA, Yancey LJ, Crump M, Stadtmauer EA, Biron P, Crown JP, Schmid P, Lotz JP, Rosti G, Bregni M, Demirer T.

High-dose chemotherapy with autologous hematopoietic stem cell transplantation in metastatic breast cancer: Overview of six randomized trials.

J Clin Oncol 2011 Aug 20;29(24):3224-31

DA Berry, NT Ueno, MM Johnson, Lei X, Caputo J, Rodenhuis S, Peters WP, Leonard RC, Barlow WE, Tallman MS, Bergh J, Nitz UA, Gianni AM, Basser RL, Zander AR, Coombes RC, Roché H, Tokuda Y, de Vries EG, Hortobagyi GN, Crown JP, Pedrazzoli P, Bregni M, Demirer T.

High-dose chemotherapy with autologous stem cell support as adjuvant therapy in breast cancer: Overview of 15 randomized trials

J Clin Oncol 2011 Aug 20;29(24):3214-23

Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, Dreger P, de Witte T, Farge-Bancel D, Gaspar B, Marsh J, Mohty M, Peters C, Tichelli A, Velardi A, de Elvira CR, Falkenburg F, Sureda A, Madrigal A; European Group for Blood and Marrow Transplantation (EBMT).

The EBMT Activity Survey: 1990-2010.

Bone Marrow Transplant. 2012 Jul;47(7):906-23

Russo V, Pilla L, Lunghi L, et al.

Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes.

Int J Cancer, 2013 Jun 1;132(11):2557-66

Russo V, Lunghi F, Fontana R, Bregni M.

A Clinical Study of a Cell-Based MAGE-A3 Active Immunotherapy in Advanced Melanoma Patients.

J Cancer. 2011;2:329-30.

Ciceri F, Bregni M, Peccatori J.

Innovative platforms for haploidentical stem cell transplantation: the role of unmanipulated donor graft.

J Cancer. 2011;2:339-40.

Bregni M, Ciceri F, Peccatori J.

Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC).

J Cancer. 2011;2:347-9.

Pedrazzoli P, Comoli P, Montagna D, Demirer T, Bregni M; EBMT STWP.
Is adoptive T-cell therapy for solid tumors coming of age?

Bone Marrow Transplant. 2012 Aug;47(8):1013-9.

Russo V, Bondanza A, Ciceri F, Bregni M, Bordignon C, Traversari C, Bonini C.
A dual role for genetically modified lymphocytes in cancer immunotherapy.

Trends Mol Med. 2012 Apr;18(4):193-200.

Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, Dreger P, de Witte T, Farge-Bancel D, Gaspar B, Marsh J, Mohty M, Peters C, Tichelli A, Velardi A, de Elvira CR, Falkenburg F, Sureda A, Madrigal A; European Group for Blood and Marrow Transplantation (EBMT).

The EBMT activity survey: 1990-2010.

Bone Marrow Transplant. 2012 Jul;47(7):906-23.

Thiel U, Wolf P, Wawer A, Blaeschke F, Grunewald TG, von Lüttichau IT, Klingebiel T, Bader P, Borkhardt A, Laws HJ, Handgretinger R, Lang P, Schlegel PG, Eyrich M, Gruhn B, Ehninger G, Koscielniak E, Klein C, Sykora KW, Holler E, Mauz-Körholz C, Woessmann W, Richter GH, Schmidt AH, Peters C, Dirksen U, Jürgens H, Bregni M, Burdach S.

Human leukocyte antigen distribution in German Caucasians with advanced Ewing's sarcoma.

Klin Padiatr. 2012 Oct;224(6):353-8.

Russo V, Pilla L, Lunghi F, Crocchiolo R, Greco R, Ciceri F, Maggioni D, Fontana R, Mukenge S, Rivoltini L, Rigamonti G, Mercuri SR, Nicoletti R, Maschio AD, Gianolli L, Fazio F, Marchianò A, Florio AD, Maio M, Salomoni M, Gallo-Stampino C, Fiacco MD, Lambiase A, Coulie PG, Patuzzo R, Parmiani G, Traversari C, Bordignon C, Santinami M, Bregni M.

Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes.

Int J Cancer. 2013 Jun 1;132(11):2557-66

Passweg JR, Baldomero H, Bregni M, Cesaro S, Dreger P, Duarte RF, Falkenburg JH, Kröger N, Farge-Bancel D, Gaspar HB, Marsh J, Mohty M, Peters C, Sureda A, Velardi A, Ruiz de Elvira C, Madrigal A; European Group for Blood and Marrow Transplantation.

Hematopoietic SCT in Europe: data and trends in 2011.

Bone Marrow Transplant. 2013 Sep;48(9):1161-7.

Procopio G, Verzoni E, Bracarda S, Ricci S, Sacco C, Ridolfi L, Porta C, Miceli R, Zilembo N, Bajetta E; Italian Trials in Medical Oncology (ITMO) group.

Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial.

Ann Oncol. 2013 Dec;24(12):2967-71

Thiel U, Koscielniak E, Blaeschke F, Grunewald TG, Badoglio M, Diaz MA, Paillard C, Prete A, Ussowicz M, Lang P, Fagioli F, Lutz P, Ehninger G, Schneider P, Santucci A, Bader P, Gruhn B, Faraci M, Antunovic P, Styczynski J, Krüger WH, Castagna L, Rohrlach P, Ouachée-Chardin M, Salmon A, Peters C, Bregni M, Burdach S; Solid Tumour Working Party and the Paediatric Disease Working Party of the European Group for Blood and Marrow Transplantation.

Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment.

Br J Cancer. 2013 Nov 12;109(10):2523-32

Pedrazzoli P, Martinelli G, Gianni AM, Da Prada GA, Ballestrero A, Rosti G, Frassinetti GL, Aieta M, Secondino S, Cinieri S, Fedele R, Bengala C, Bregni M, Grasso D, De Giorgi U, Lanza F, Castagna L, Bruno B, Martino M; of Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule staminali emopoietiche e terapia cellulare (GITMO) – Sezione Tumori Solidi.

Adjuvant High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for High-Risk Primary Breast Cancer: Results from the Italian National Registry.

Biol Blood Marrow Transplant. 2013 Dec 27. pii: S1083-8791(13)01184-1